Bogart Group has sold 100% of its Israeli subsidiary, April Cosmetics and Perfumes Store Chain Ltd., to April Holding D.K. Ltd. The buyer belongs to David Konckier, Bogart's own Chairman, CEO and majority shareholder. The board approved the transaction on October 12, 2026.

The French group, whose brands include Jacques Bogart, Ted Lapidus and Carven and whose retail arms include DI Drugstores and HC Parfümerie, says the divestment will strengthen its financial position and improve how it allocates resources. In plainer terms: the company is trimming a perimeter and pulling cash and management attention back toward the core.

Who is buying, and why does the buyer matter?

The structure is the story here. The acquirer, April Holding D.K. Ltd., is not a strategic outsider but a vehicle controlled by the man who already runs the seller. Konckier holds both the chairman's gavel and the chief executive's desk at Bogart, and he is the group's majority shareholder. Related-party transactions of this kind concentrate the interest neatly: the same person sits on both sides of the table.

For a listed French operator, that overlap invites scrutiny. Boards typically lean on independent directors and fairness opinions precisely because the seller's fiduciary duty runs to all shareholders, while the buyer's advantage runs to one. Bogart has not disclosed the price in the information available, so the market cannot yet judge whether the balance tilted.

What does the sale change for the group?

Three practical effects follow from the divestment, as far as the announcement allows:

• Financial position. Bogart frames the deal as a balance-sheet move, converting an Israeli operating asset into cash or cleaner allocation capacity.
• Resource allocation. Management signals it wants capital and attention concentrated elsewhere — presumably the fragrance brands and the European retail chains that carry them.
• Footprint. The group loses a direct Israeli owned-and-operated chain, April, which had sat inside its portfolio alongside the drugstore and perfumery networks.

For suppliers and brand partners, the message is that April's Israeli stores now sit with a new owner. Contracts, listings and terms negotiated with Bogart's subsidiary will need counterparty review. For competitors in Israeli beauty retail, a locally owned and personally motivated operator has just entered the arena.

What should watchers look at next?

The price is the missing number. Once Bogart publishes the transaction value and any terms — earn-outs, warranties, payment schedule — analysts can test the "strengthen the financial position" claim against the actual consideration.

Watch the group's next results release for how the disposal is treated: a discontinued-operation line, a capital gain or loss, and any guidance revision. That filing, plus any regulatory disclosure on the related-party approval process, will tell investors whether October 12, 2026 marks a tidy refocusing or a discount quietly handed to the majority shareholder.

Until then, the deal is a one-line story with a familiar cast: the boss bought the business. The next data point that matters is the number on the invoice.